Zydus Lifesciences Ka 'Orphan Drug' Jackpot! USFDA Ne Di Sickle Cell Therapy Ko Manzoori, Share Price Ka Kya Hoga?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Zydus Lifesciences Ka 'Orphan Drug' Jackpot! USFDA Ne Di Sickle Cell Therapy Ko Manzoori, Share Price Ka Kya Hoga?
Overview

Arre bhaiyo, Zydus Lifesciences ke liye ek badi khabar hai! USFDA ne unki Sickle Cell Disease (SCD) wali dawa, Desidustat, ko 'Orphan Drug Designation' (ODD) de diya hai. Iska matlab hai ki rare diseases pe company ka focus badh raha hai, aur isse **7 saal** tak ki market exclusivity milne ke chance hain. Ye news aise time pe aayi hai jab Zydus, Ardelyx ko kharidne ki baat kar rahi hai, aur pichhle ek saal mein stock thoda neeche bhi aaya tha. Desidustat ka Phase II trial bhi complete ho gaya hai.

USFDA Ka 'Orphan Drug' Status: Desidustat Ke Liye Badi Jeet!

Dekho, USFDA ne Zydus Lifesciences ko unki Sickle Cell Disease (SCD) wali dawa, Desidustat, ke liye 'Orphan Drug Designation' (ODD) de diya hai. Ye SCD jaise rare diseases ko target karne wali companies ke liye ek bahut bada regulatory win hota hai. Ye status un drugs ko milta hai jo kam logo ko hone wali bimariyon ka ilaaj karti hain, jaise US mein 2 lakh se kam log affected hon. Is ODD se Zydus ko tax credits, user fees mein chhoot, aur sabse important, approval ke baad 7 saal tak exclusive marketing rights mil sakte hain. History dekhein toh aise ODD announcements ke baad stocks mein average 3.36% ka jump dikha hai. Desidustat khud ek HIF-PHI inhibitor hai, aur Zydus ne iska Phase II trial complete kar liya hai, jiska data abhi aane wala hai.

Zydus Ka Stock Aur Valuation: Kaisa Chal Raha Hai?

Ab company ke stock ki baat karein toh, February 2026 ki shuruaat tak iski market cap ₹887.78 Billion thi. Jan 2026 mein TTM P/E ratio lagbhag 18.35 tha, jo Sun Pharma (P/E 33.52) ya Divi's Lab (P/E 63.97) jaise competitors se kaafi attractive lagta hai. Haalanki, pichhle saal stock 11.97% gir chuka hai aur abhi ₹887.50 ke aas paas trade kar raha hai. Technical indicators bhi 'Strong Sell' ka ishara de rahe hain, jaise ki 14-day RSI 41.24 par hai. Is context mein ye ODD bahut valuable ho jaata hai.

Ardelyx Acquisition Ki Khujli?

Aur ek badi khabar ye hai ki Zydus, Ardelyx ko acquire karne ki baat kar rahi hai. Ardelyx ki market cap $1.87 Billion hai aur wo filhaal loss mein chal rahi hai (P/E approx -33.3x). Ye acquisition Zydus ke pipeline ko US market mein strong kar sakta hai, aur company iske liye QIP (Qualified Institutional Placement) jaise funding options bhi explore kar rahi hai.

Sickle Cell Market Aur Sector Ka Trend

Sickle Cell Disease (SCD) market mein kaafi innovation ho raha hai. Late 2023 mein FDA ne gene therapies jaise Casgevy aur Lyfgenia ko approve kiya tha. Vertex Pharmaceuticals bhi SCD research mein active hai. Toh Desidustat ek competitive field mein enter karegi. Overall biotech sector, jo NASDAQ Biotechnology Index (NBI) se track hota hai, pichhle saal ~26.5% badha hai. Rare disease stocks ko generally acha valuation milta hai (median EV/Revenue around 6.2x tha Q4 2024 mein).

Analysts Kya Bolte Hain Aur Future Plan

Analysts ke views Zydus par mixed hain. Kuch 'BUY' recommend kar rahe hain target ₹500 ke aas paas, toh kuch 'Sell' signal de rahe hain. Lekin haan, kuch reports mein average target price ₹1041 bhi bataya gaya hai. Zydus ka focus complex injectables aur orphan drugs pe badhana ek smart move lag raha hai jo company ko future mein fayda de sakta hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.